TickerFacts.

Zhengye Biotechnology Holding Ltd (ZYBT): Cost of Revenue

Annual figures by period end, from SEC filings.

92.49M CNY
Year ended 2025-12-31
-6.3%
3-year compound annual growth
112.39M CNY2022-12-31: 112.39M CNY2023-12-31: 94.14M CNY2024-12-31: 95.06M CNY2025-12-31: 92.49M CNY92.49M CNY
2022-12-31 Cost of Revenue (CNY) 2025-12-31
Period endedCost of RevenueChange YoYSource filing
2025-12-3192.49M CNY-2.7%2026-04-28, From 2025-01-01
2024-12-3195.06M CNY+1.0%2026-04-28, From 2024-01-01
2023-12-3194.14M CNY-16.2%2026-04-28, From 2023-01-01
2022-12-31112.39M CNYn/a2025-07-03, From 2022-01-01

Cost of Revenue at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCost of RevenueChange YoY
Zhengye Biotechnology Holding Ltd (ZYBT)2025-12-3192.49M CNY-2.7%
Yatsen Holding Ltd (YSG)2025-12-31936.78M CNY+20.7%

Compare ZYBT, YSG side by side · Screen every company in Pharmaceutical Preparations ↗